Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1.
Explore this paper's citation graph
Summary
Gefitinib in combination with gemcitabine and cisplatin in chemotherapy-naive patients with advanced NSCLC did not have improved efficacy over gemcitABine and cascplatin alone, and the reasons for this remain obscure and require further preclinical testing.
- Type
- article
- Published
- 2004-03-01
- Cited by
- 1,794
- References
- 19
- Access
- Open access
- OpenAlex
- https://openalex.org/W2110835998
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:8928343
Keywords
Gefitinib, Medicine, Gemcitabine, Tolerability, Internal medicine
References
- Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase.
- Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer.
- [New guidelines to evaluate the response to treatment in solid tumors].
- Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.
- The epidermal growth factor receptor and its inhibition in cancer therapy.
- On closed test procedures for dose-response analysis.
- Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer.
- O-242 Gefitinib (‘Iressa’, ZD1839) monotherapy for pretreated advanced non-small-cell lung cancer in IDEAL 1 and 2: tumor response is not clinically relevantly predictable from tumor EGFR membrane staining alone
- Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial.
- Severe acute interstitial pneumonia and gefitinib.
- Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2.
- Randomized phase III study of gemcitabine-cisplatin versus etoposide-cisplatin in the treatment of locally advanced or metastatic non-small-cell lung cancer.
- Epidermal growth factor receptor dependence in human tumors: more than just expression?
- Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor.
- Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials
- Recommendations guiding physicians in biomedical research involving human subjects. World Medical Association Declaration of Helsinki.
Cited by
- Analyzing the Impact of EGFR-induced c-Met Phosphorylation in Non-Small Cell Lung Cancer
- Tumor dormancy and metastasis.
- Molecular therapy of head and neck cancer
- Advances in cytotoxic chemotherapy for the treatment of metastatic or recurrent non-small cell lung cancer.
- Integration of Novel Therapeutics into Combined Modality Therapy of Locally Advanced Non–Small Cell Lung Cancer
- Tyrosine kinases as targets for cancer therapy.
- Preclinical Evaluation of ZD1839 Alone or in Combination with Oxaliplatin in a Panel of Human Tumor Cell Lines – Implications for Clinical Use
- Erlotinib in the treatment of non-small cell lung cancer
- Adjuvant chemotherapy for non-small cell lung cancer.
- Mutations of the epidermal growth factor receptor in non-small cell lung cancer -- search and destroy.
- Anti-cancer therapy with EGFR inhibitors: factors of prognostic and predictive significance.
- Recent trends in the treatment of advanced lung cancer
- Clinical development of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors: what lessons have we learned?
- Targeted therapy of advanced non-small cell lung cancer: the role of bevacizumab
- Interstitial lung disease associated with epidermal growth factor receptor tyrosine kinase inhibitor therapy in non-small-cell lung carcinoma.
- Cetuximab rescue a patient with non-small cell lung cancer from rapid disease progression during chemotherapy
- Responses of cancer cells with wild-type or tyrosine kinase domain-mutated epidermal growth factor receptor (EGFR) to EGFR-targeted therapy are linked to downregulation of hypoxia-inducible factor-1α
- Randomized phase II study of cetuximab plus cisplatin/vinorelbine compared with cisplatin/vinorelbine alone as first-line therapy in EGFR-expressing advanced non-small-cell lung cancer.
- Developments in Epidermal Growth Factor Receptor-Targeting Therapy for Solid Tumors: Focus on Matuzumab (EMD 72000)
- Update on Anti-EGFR Therapy
Related papers
- Tolerability of gefitinib in patients receiving treatment in everyday clinical practice
- Evaluation of the epidermal growth factor receptor gene mutation and copy number in non-small cell lung cancer with gefitinib therapy.
- Exon 19 Deletion Mutations of Epidermal Growth Factor Receptor Are Associated with Prolonged Survival in Non–Small Cell Lung Cancer Patients Treated with Gefitinib or Erlotinib
- Efficacy of gefitinib for elderly patients with advanced non-small cell lung cancer harboring epidermal growth factor receptor gene mutations: a retrospective analysis.
- Analysis of a single-codon E746 deletion in exon 19 of the epidermal growth factor receptor
- PD-149 Epidermal growth factor receptor (EGFR)-activating mutations(mut) and response to gefitinib in lung adenocarcinomas
- Predictive factors for epidermal growth factor receptor inhibitors--the bull's-eye hits the arrow.
- Analysis of epidermal growth factor receptor expression as a predictive factor for response to gefitinib (‘Iressa’, ZD1839) in non-small-cell lung cancer
- Surgical resection of locally advanced epidermal growth factor receptor (EGFR) mutated lung adenocarcinoma after gefitinib and review of the literature.